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The MICA gene encodes for major histocompatibil-
ity complex class I chain-related proteins (MIC),
which belong to a recently identi®ed new family of
nonclassical major histocompatibility complex mol-
ecules. The general structure of the MICA molecule
resembles that of major histocompatibility complex
class I molecules. MIC molecules are considered to
be stress-induced antigens that are recognized by
cytotoxic T cells and natural killer cells, which play
an important role in the surveillance of transformed
infected and damaged cells. Associations of major
histocompatibility complex class I molecules with
skin cancer have been described before. To evaluate
the possible association of MICA gene polymorphism
with the risk for nonmelanoma skin cancer we evalu-
ated 153 cases with squamous cell carcinoma, 261
cases with basal cell carcinoma, 111 controls with
malignant melanoma, and 247 controls without a
history of skin cancer. Five distinct MICA alleles A4,
A5, A6, A9, and A5.1 were studied. As the MICA 5.1
variant gene contains a four-nucleotide insertion that
causes a stop codon in the trans membrane region,
the resulting truncated MICA molecule does not
reside on the cellular membrane. In the case of
individuals who are homozygous for MICA 5.1 this
results in cells that are naked for the MICA
molecule. We therefore speci®cally addressed the
possible association between MICA 5.1 homozygos-
ity and skin cancer, as these individuals are expected
to be at the highest risk for skin cancer if the MICA
gene plays a role in skin carcinogenesis. Viral
proteins may serve as antigens for recognition of
skin cancer by the immune system. Human papillo-
mavirus is the most likely candidate virus to be
involved in the carcinogenesis of cutaneous squa-
mous cell carcinoma. Hence, we also assessed
the association between MICA polymorphism and
squamous cell carcinoma in human-papillomavirus-
positive and human-papillomavirus-negative individ-
uals as identi®ed by the presence of human
papillomavirus DNA in hairs plucked from their
eyebrows. Our analyses did not reveal any signi®cant
differences regarding the MICA allele frequencies
between cases and controls. Also homozygotes and
heterozygotes for the MICA 5.1 variant gene were
not at an increased risk for skin cancer compared to
individuals without this variant gene and infection
with human papillomavirus did not materially in¯u-
ence these ®ndings. The same group of cases and
controls was large enough to show an association
between melanocortin 1 receptor gene polymorph-
ism and skin cancer and to reasonably exclude an
association between p53 codon 72 polymorphism
and skin cancer. Therefore, we conclude that an
association between MICA gene polymorphism and
nonmelanoma skin cancer is not likely. Key words:
epidemiology/human leukocyte antigen/major histocompat-
ibility complex/MICA (MHC class I chain related gene A)
polymorphism/skin cancer. J Invest Dermatol 118:686±691,
2002
T
he human leukocyte antigen (HLA) system plays an
important role in cellular immune responses to viral
and tumor antigens (Segall and Bach, 1990; Klitz,
1992; Monaco, 1992; Bouwes Bavinck and Claas,
1994). T lymphocyte recognition requires both
foreign antigen and self major histocompatibility complex
(MHC) molecules. Both HLA class I and II molecules have been
implicated in the development of skin cancer. Associations of HLA
molecules with basal cell carcinoma and squamous cell carcinoma
have been described in both immunocompetent and renal
transplant patients (Cerimile et al, 1988; Bouwes Bavinck and
Claas, 1994; Czarnecki et al, 1994; Bouwes Bavinck et al, 2000).
Speci®cally, the class I molecules HLA-A3 and HLA-B27 and the
class II molecule HLA-DR7 have been associated with an increased
risk of skin cancer. The class I molecule HLA-A11 and the class II
molecule HLA-DR4 were associated with a decreased risk
(Bouwes Bavinck and Claas, 1994; Bouwes Bavinck et al, 2000).
Not all studies, however, could show an association between HLA
molecules and skin cancer (Espana et al, 1995).
Recently a new family of nonclassical MHC molecules, the
MHC class I chain-related protein (MIC), encoded by genes in the
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MHC have been identi®ed (Bahram, 2000). MIC molecules are
considered to be stress-induced antigens that are recognized by
cytotoxic T cells and natural killer cells, which play an important
role in the surveillance of transformed infected and damaged cells
(Steinle et al, 1998; Bauer et al, 1999; Diefenbach and Raulet, 1999;
Lopez-Botet and Bellon, 1999; Lanier, 2000). MIC genes are
currently considered to be the most divergent mammalian MHC
genes known (Bahram and Spies, 1996; Zwirner et al, 1998;
Bahram, 2000).
The MICA gene is a member of the MIC family (Robinson et al,
2001). Other members of the MIC family are the MICB, MICC,
MICD, and MICE genes. Only MICA and MICB are functional
genes; they have an open reading frame and encode cell surface
expressed molecules (Bahram and Spies, 1996; Bahram et al, 1996;
Fodil et al, 1996; Bahram, 2000). MICC, MICD, and MICE are
considered pseudogenes. The MICA gene has been identi®ed
46.4 kb centromeric to the HLA-B gene and telomeric to HLA-
DQ and the tumor necrosis factor locus on the short arm of human
chromosome 6 (Bahram and Spies, 1996; Mizuki et al, 1997).
Given the very short distance separating the MICA gene from
HLA-B, a vigorous degree of positive linkage disequilibrium can be
expected (Mizuki et al, 1997; Bahram, 2000).
Like other HLA class I genes, the MICA and MICB genes
encode for a1, a2, and a3 extracellular domains, a transmembrane
region, and a carboxyl terminal cytoplasmic tail (Ota et al, 1997).
Recent studies have demonstrated polymorphic (GCT)n triplet
repeats in the transmembrane region (exon 5) of the MICA gene
(Mizuki et al, 1997). These polymorphisms are designated A4, A5,
A6, A9, and A5.1, representing four, ®ve, six, and nine copies of
(GCT), and (GCT)4(GGCT), respectively (Mizuki et al, 1997;
Cheng et al, 2000). The general structure of the MICA molecule
resembles that of MHC class I molecules (Bahram, 2000). In
contrast to class I molecules, however, no antigen appears to be
presented in the MICA putative antigen-binding groove (Bahram,
2000).
Unlike the classical (and most nonclassical) MHC-I genes, MIC
genes are not ubiquitously expressed (Bahram, 2000). In fact, their
transcripts are not detectable in cells of lymphohematopoetic
lineage (Bahram, 2000). MICA molecules, however, are frequently
expressed on monocytes, endothelial cells, epithelial cells, ®bro-
blasts, and keratinocytes, especially under stress conditions (Zwirner
et al, 1998; 1999). MICA molecules are also frequently expressed in
epithelial tumors (Bauer et al, 1999; Groh et al, 1999). MICA
molecules have been identi®ed in cancer cell lines such as Raji
(Burkitt's lymphoma) and MOLT-4 (acute lymphoblastic leuke-
mia).
Not all MICA variant genes encode for MICA molecules that
reside on the cellular membrane (Mizuki et al, 1997). Speci®cally,
the MICA 5.1 variant gene, which is characterized by a four-
nucleotide insertion that causes a frameshift mutation resulting in a
premature termination by a stop codon (TAA) in the transmem-
brane region, only encodes a secreted, soluble MICA molecule
(Mizuki et al, 1997). This truncated MICA molecule does not
reside on the cellular membrane, which, in the case of MICA 5.1
homozygotes, results in cells that are naked for the MICA molecule
(Mizuki et al, 1997).
A receptor for the MICA molecule, identi®ed as NKG2D, has
been expressed mainly on gamma delta T cells (gd T cells), CD8-
positive alpha beta T cells (ab T cells) and natural killer cells (Groh
et al, 1996; 1998; Bauer et al, 1999). Engagement of NKG2D
activates cytolytic responses of gd T cells and natural killer cells
against transfectants and epithelial tumors expressing the MICA
molecule (Bauer et al, 1999). Because NKG2D is also present on
most CD8 ab T cells it may also modulate antigen-speci®c T cell
responses, depending on whether MIC molecules are induced on
the surface of pathogen-infected cells (Groh et al, 2001). In this way
NKG2D could function as a costimulatory receptor.
The high levels of MICA molecules in epithelial cell lines
together with the upregulation of MICA molecules after heat shock
stress may represent a new molecular mechanism exposing stressed
epithelial cells to the immune system (Groh et al, 1998). Earlier
studies have reported HLA associations with skin cancer (Bouwes
Bavinck and Claas, 1994) but similar studies have not yet been
reported for MICA polymorphisms. The presence of MICA
molecules in keratinocytes suggests that MICA could play a role in
the pathogenesis of skin cancer. There are several ways by which
MICA molecules could play a role, e.g., through the presentation
of tumor antigens or viral antigens.
If viral antigens are considered, the most likely candidate virus to
be involved in nonmelanoma skin carcinogenesis (speci®cally
squamous cell carcinoma) is thought to be human papillomavirus
(HPV) although the exact role of this virus is still unclear (P®ster
and ter Schegget, 1997; Bouwes Bavinck et al, 2001). The earliest
evidence that HPV infection may play a role in nonmelanoma skin
carcinogenesis comes from studies in patients with the rare
hereditary syndrome epidermodysplasia verruciformis (EV) (Orth,
1987). There are several arguments in favor of, but also some
arguments against, a causative role of HPV infection in the
development of squamous cell carcinomas in immunocompetent
and immunosuppressed individuals (reviewed in Bouwes Bavinck et
al, 2001). To be informed about the EV-HPV infection status of
our patients and controls, we determined the presence of EV-HPV
DNA in eyebrow hair plucked from cases with squamous cell
carcinoma and from controls (Boxman et al, 1997, 2000).
We evaluated 153 cases with squamous cell carcinoma, 261 cases
with basal cell carcinoma, 111 controls with malignant melanoma,
and 247 controls without skin cancer to evaluate the possible
association of MICA gene polymorphism with the development of
nonmelanoma skin cancer. Five distinct alleles A4, A5, A6, A9, and
A5.1 were studied. The risk of skin cancer was speci®cally
addressed in individuals who were MICA 5.1 homozygotes, as
these individuals do not express MICA molecules on their
keratinocytes and, hypothetically, should carry the highest risk of
skin cancer, if MICA genes play a role in skin carcinogenesis. We
anticipated ®nding an association of MICA gene polymorphism
with squamous cell carcinoma and no association with malignant
melanoma, whereas a weak association could be expected with
basal cell carcinoma. The association between MICA gene
polymorphism and squamous cell carcinoma was also studied in
HPV-positive and HPV-negative individuals, separately, to appraise
a possible role of HPV infection.
MATERIALS AND METHODS
Study population For this study we selected 365 nonmelanoma skin
cancer cases (153 cases with squamous cell carcinoma, 261 cases with
basal cell carcinoma), 111 controls with malignant melanoma, and 247
controls without skin cancer. These individuals were selected from a
larger case-control study, which has been denoted the Leiden Skin
Cancer Study (Bastiaens et al, 2001b; De Hertog et al, 2001; Kennedy et
al, 2001).1 In short, the Leiden Skin Cancer Study is a hospital-based
case-control study, including 161 patients with squamous cell carcinoma,
301 with nodular basal cell carcinoma, 153 with super®cial multifocal
basal cell carcinoma, 125 with malignant melanoma, and 386 controls
(De Hertog et al, 2001). A total of 135 patients had two or more
different types of skin cancer (Bastiaens et al, 2001b; De Hertog et al,
2001). In this study we pooled the two different types of basal cell
carcinoma, resulting in 64 patients with two or three types of skin
cancer.
Cases were men and women, aged between 30 and 80 y, with
histologically proven squamous cell carcinoma or basal cell carcinoma.
Squamous cell carcinoma and basal cell carcinoma cases were newly
1Members of the Leiden Skin Cancer Study are, in alphabetical order,
Nathalie van Amsterdam, Maarten T. Bastiaens, Wilma Bergman, Marjo
J.P. Berkhout, Jan N. Bouwes Bavinck, Ingeborg L.A. Boxman, ReneÂ
Broer, Jan A. Bruijn, Marianne Crijns, Mariet Feltkamp, Nelleke A. Gruis,
So®e A.E. De Hertog, Juliette J. Hoefnagel, Jeanet A.C. ter Huurne, Kees
Kennedy, Christine J. Kielich, Iris Kuijken, Sjan P.M. Lavrijsen, Linda
H.C. Mulder, Marloes Polderman, Marinus C.G. van Praag, Jan ter
Schegget, Caesar Sterk, Linda Struijk, Jan P. Vandenbroucke, Bert J.
Vermeer, Christianne A.H. Wensveen, Rudi G.J. Westendorp.
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diagnosed between January 1985 and December 1997 at the Department
of Dermatology of the Leiden University Medical Center. Malignant
melanoma controls consisted of patients with nonfamilial cutaneous
malignant melanoma of the skin, who were newly diagnosed between
January 1991 and April 1998 (De Hertog et al, 2001).
Controls without skin cancer in the same age range were recruited at
the ophthalmology outpatient clinic of the Leiden University Medical
Center (De Hertog et al, 2001). This group was chosen because it
consists of patients of the same University Hospital and living in the
same region. These controls were excluded when they either had
intraocular melanoma or any skin cancer in their history. Both cases and
controls were excluded when they were transplant recipients, or suffered
from rare hereditary skin disorders such as xeroderma pigmentosum,
basal cell nevus syndrome (Gorlin's syndrome), or were members of
familial atypical multiple mole melanoma families, as these persons are at
an increased risk of developing skin cancer. Persons with a dark skin
(Fitzpatrick classi®cation V and higher) (Fitzpatrick, 1988), both case
subjects and controls, were also excluded, as persons with these skin
types rarely develop skin cancers (De Hertog et al, 2001).
MICA gene analysis DNA was isolated using the salting out method
as previously described (Miller et al, 1988) and adjusted to 100 ng per ml.
The following primers were used: ¯anking primer, MICA forward 5F 5,
CCTTTTTTTCAGGGAAAGTGC; reverse MICA 5R 5,
CCTTACCATCTTCCAGAAACTGC.
The 5F primer was labeled with ¯uorescent amadite (Isogen
Bioscience, The Netherlands). It corresponds to the boundary region
with 12 nucleotides in intron 4, whereas the reverse primer is located in
intron 5 of the transmembrane region. The ampli®cation was performed
in 50 ml reaction volume containing 1 ml genomic DNA, 25 pmol of
each primer, 2.5 Taq polymerase (Perkin Elmer, The Netherlands). The
ampli®cation buffer contained 50 mM KCl, 10 mmol Tris±HCl, pH 8.4,
2 mM MgCl2, 1.25% glycerol, and 200 mM of each deoxyribonucleoside
triphosphate (DNTPs). The ampli®cation was performed in two steps to
increase the speci®city of primer annealing during the ®rst eight cycles
on a Peltier Thermal Cycler (PTC-200 MJ Research). The polymerase
chain reaction (PCR) was carried out as a touch-down ampli®cation.
The reaction mixture was subjected to one cycle of denaturation at 95°C
for 5 min followed by eight cycles of denaturation at 94°C for 30 s and
an annealing temperature of 68°C ± 1°C per cycle in the ®rst eight
cycles. Extension was performed at 72°C for 30 s. After the eight cycles
the ampli®cation was done for 30 cycles at 94°C for 30 s, annealing at
60°C for 30 s, and extension at 72°C for 30 s.
Finally, the PCR was ®nished by an extension at 72°C for 5 min.
The PCR product was always controlled by an electrophoresis on a 2%
agarose gel. The product was then loaded on a standard denaturation
sequence gel comprising 6% polyacrylamide 0.6 TBE (Tris, boric acid,
ethylenediamine tetraacetic acid) in an automated laser ¯uorescein DNA
sequencer (ALF Pharmacia Biot). The electrophoresis was performed on
2000 V, 50 mA, 50 W, and 3 mW laser power at 50°C. Details about
gel, buffers, and DNA sequencer were as described by the manufacturer.
For accurate allele sizing we used four internal allelic ladders and two
external size markers covering the range of the MICA microsatellites.
The data were analyzed with the Fragment Manager (FM) software made
available by the manufacturer.
EV-HPV analyses Eyebrow hairs were used as a measurement to
determine the EV-HPV infection status in cases with squamous cell
carcinoma and controls. Viral DNA isolated from eyebrow hairs is a
good marker of HPV infections elsewhere on the body (Boxman et al,
2000). The same EV-HPV types can be detected in hair samples from
different body sites collected at the same time point (Boxman et al, 1997)
and in skin lesions from the same individual collected over time
(Berkhout et al, 2000). About eight to 10 hairs were plucked from
eyebrows by using a disposable pair of tweezers and gloves for each
individual (Boxman et al, 2000). DNA extraction from the cells attached
to the plucked hairs has been described earlier (Boxman et al, 2000) and
was performed according to the Boom et al (1990) DNA extraction
method.
A slightly modi®ed nested PCR method was used to detect EV-HPV
DNA (Berkhout et al, 1995; Boxman et al, 1997, 2000) using the primer
set Ma for the ®rst step of the PCR ampli®cation and the primer set Ha
for the second step (Bastiaens et al, 2001a).
Statistical analyses c2 analysis was used to compare MICA allele
frequencies in controls and in patients with squamous cell carcinoma,
basal cell carcinoma, or malignant melanoma. Odds ratios with 95%
con®dence intervals (CI) were calculated as an estimation of the relative
risks of squamous cell carcinoma, basal cell carcinoma, and malignant
melanoma for individuals who were homozygotes or heterozygotes for
the MICA 5.1 allele, compared with individuals without the MICA 5.1
allele. In the general population the anticipated frequency for individuals
who are homozygotes for the MICA 5.1 allele is 30%. With a power of
80% and a 1 ± a of 95% in a 1:2 case-control design, 132 cases and 264
controls suf®ce to show a difference of 15%, i.e., a frequency of 45% in
the cases, which corresponds to an odds ratio of 1.9 (EpiInfo version
6.04b, January 1997, Center for Disease Control and Prevention, U.S.A.,
and World Health Organization, Geneva, Switzerland). These analyses
were also performed separately for HPV-positive and HPV-negative
individuals.
RESULTS
Baseline characteristics of the study population Table I
represents the gender and age distribution of the study population.
There were 458 individuals with skin cancer and 247 controls. Out
of the skin cancer cases 46 individuals had both squamous cell
carcinoma and basal cell carcinoma. Four individuals had both
squamous cell carcinoma and malignant melanoma. Twelve
melanoma cases also had a basal cell carcinoma and two cases
were af¯icted with all three types of skin cancer. Men were over-
represented among the individuals with nonmelanoma skin cancer,
whereas women were more frequently present among the
individuals with malignant melanoma and the controls. The
individuals with nonmelanoma skin cancer were signi®cantly
older, whereas the individuals with malignant melanoma were
signi®cantly younger than the control group.
Frequency of mica alleles is not associated with skin
cancer Table II presents the MICA allele frequencies in skin
cancer cases and controls. Triplet repeat polymorphisms in the
transmembrane region identi®ed as A4, A5, A6, A9, and A5.1 were
evaluated in both cases and controls. No signi®cant differences
were observed between cases and controls in this study. Compared
to the other alleles, the A5.1 allele was the most common allele
observed in this population. Additionally, no association between
MICA gene polymorphism and skin cancer was observed if the
frequency of these alleles in the individual cases and controls were
considered (data not shown). The results suggest that MICA gene
polymorphism is not associated with an increased risk for the
occurrence of either nonmelanoma or melanoma skin cancer.
Homozygosity for the MICA 5.1 allele does not impose a
higher risk for skin cancer As the MICA 5.1 variant gene does
not encode for a MICA molecule that resides on the cellular
membrane, which, in the case of MICA 5.1 homozygotes, results in
cells that are naked for the MICA molecule, we speci®cally assessed
the risk of skin cancer in individuals who were homozygotes for
this variant gene. Table III shows that homozygotes and
heterozygotes for the MICA 5.1 variant gene were not at an
increased risk for skin cancer compared to individuals without this
variant gene.
No association between MICA polymorphism and
squamous cell carcinoma was seen in individuals with or
without infection with HPV Infection with EV-HPV was
assessed in cases with squamous cell carcinoma and in controls,
because this virus is suspected to be involved in the pathogenesis of
squamous cell carcinoma. In a total of 110 out of 141 (78.0%) cases
with squamous cell carcinoma tested and in 142 out of 195 (72.8%)
controls tested, DNA of EV-HPV could be detected in hairs
plucked from the eyebrows (p = 0.28). No signi®cant in¯uence of
the MICA 5.1 allele on the risk of squamous cell carcinoma could
be noted in either group of individuals. The risk of squamous cell
carcinoma in individuals who were heterozygotes for the MICA
5.1 allele was 1.40 (0.71±2.80) in individuals with HPV-positive
eyebrow hairs and 1.05 (0.29±3.84) in individuals with HPV-
negative eyebrow hairs. Similarly, the risk of squamous cell
carcinoma in individuals who were homozygotes for the MICA
5.1 allele was 1.08 (0.53±2.20) in individuals with HPV-positive
eyebrow hairs and 1.44 (0.42±5.08) in individuals with HPV-
negative eyebrow hairs. Additionally, the individual MICA allele
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frequency distributions between cases with squamous cell
carcinoma and controls were comparable in EV-HPV-positive
and EV-HPV-negative individuals (data not shown).
DISCUSSION
In contrast to earlier reports, in which the association between
HLA molecules and skin cancer could be established (Cerimile et al,
1988; Bouwes Bavinck et al, 1991, 2000; Czarnecki et al, 1994), in
this large case-control study we were not able to identify an
association between MICA gene polymorphism and the occurrence
of either melanoma or nonmelanoma skin cancer. Also individuals
who were homozygotes for the MICA 5.1 allele and who,
supposedly, do not express a MICA molecule on their keratino-
cytes did not show an increased risk for skin cancer. An association
between MICA gene polymorphism and squamous cell carcinoma
could also be excluded in subgroups of individuals who did or did
not carry EV-associated HPV in hairs plucked from their eyebrows.
Earlier publications of our group, using the same cases and
controls, e.g., reporting the association between melanocortin 1
receptor gene polymorphism and skin cancer, have revealed that
the size of this study is large enough to show an association between
a genetic polymorphism and skin cancer, if this association exists
(Bastiaens et al, 2001b; Kennedy et al, 2001). In addition, the size of
this study was also large enough to reasonably exclude an
association between p53 codon 72 polymorphism and skin cancer
(Bastiaens et al, 2001a). Considering the fair size of this study we
conclude that an association between MICA gene polymorphism
and skin cancer is not likely.
Table I. Characteristics of individuals with squamous cell carcinoma, basal cell carcinoma, malignant melanoma, and
controls
Controls
(n = 247)
Squamous cell carcinomaa
(n = 153)
Basal cell carcinomaa
(n = 261)
Malignant melanomaa
(n = 111)
Gender: N (%)
Women 145 (58.7) 56 (36.6) 112 (42.9) 69 (62.2)
Men 102 (41.3) 97 (63.4) 149 (57.1) 42 (37.8)
Age (y)
Mean 6 SD 58.7 6 10.9 66.1 6 8.1 63.0 6 9.5 49.9 6 12.4
Range 35.0±79.9 43.1±77.9 31.7±78.1 24.1±77.5
aSixty-four patients had two or three different types of skin cancer.
Table II. Allele frequencies of the polymorphism in the trans membrane region (exon 5) of the MICA gene in individuals
with skin cancer and controls
MICA alleles
n (%)
Controls
(n = 494)
Squamous cell
carcinoma
(n = 306)
Basal cell
carcinoma
(n = 522)
Malignant
melanoma
(n = 222)
A4 44 (8.9) 27 (8.8) 54 (10.3) 25 (11.3)
A5 56 (11.3) 33 (10.8) 60 (11.5) 22 (9.9)
A6 69 (14.0) 38 (12.4) 69 (13.2) 33 (14.9)
A9 69 (14.0) 42 (13.7) 73 (14.0) 22 (9.9)
A5.1 256 (51.8) 166 (54.3) 266 (51.0) 120 (54.0)
p-value vs controls 0.96 0.95 0.48
Table III. Frequency of MICA 5.1 homozygosity and heterozygosity in relation to skin cancer
Controls
(n = 247)
Squamous cell
carcinomaa
(n = 153)
Basal cell
carcinomaa
(n = 261)
Malignant
melanomaa
(n = 111)
No A5.1 allele 75 (30.4) 37 (24.2) 79 (30.3) 29 (26.1)
Heterozygotes
for A5.1 allele
88 (35.6) 66 (43.1) 98 (37.5) 44 (39.7)
Homozygotes
for A5.1 allele
84 (34.0) 50 (32.7) 84 (32.2) 38 (34.2)
Odds ratio 1 1.52 1.06 1.29
(95% CI)
for heterozygotes
(0.89; 2.61) (0.67; 1.66) (0.71; 2.36)
Odds ratio
(95% CI)
for homozygotes
1 1.21
(0.69; 2.12)
0.95
(0.60; 1.51)
1.17
(0.63; 2.17)
aSixty-four patients had two or three different types of skin cancer.
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This ®nding is in accordance with a recent study evaluating a
possible role of MICA gene polymorphism in the pathogenesis of
cervical intraepithelial neoplasia (Ghaderi et al, 1999). Similar to
cutaneous squamous cell carcinoma, cervical carcinoma is associ-
ated with HLA molecules (Bontkes et al, 1998), and cervical
carcinoma is also associated with HPV infection (zur Hausen,
2000). In Ghaderi et al's study the association of MICA gene
polymorphism among 74 women who developed cervical
intraepithelial neoplasia and 153 control women was addressed.
None of the MICA alleles were associated with disease, although
the frequency of the MICA 5 allele was higher among HPV 18
seropositive patients, but this difference was not signi®cant after the
correction of p-value (Ghaderi et al, 1999).
There were several pathophysiologic rationales for studying
MICA gene polymorphism in relation to skin cancer. First, MICA
molecules that are expressed on keratinocytes especially under stress
conditions could have evoked an immune response from natural
killer cells. Natural killer cells attack, among others, tumor cells
(Diefenbach and Raulet, 1999). It is conceivable that MICA
molecules could have been upregulated in skin cancer cells,
triggering natural killer cells via their receptor, NKG2D. In this
way natural killer cell responses against MICA-molecule-bearing
tumors could have been induced (Wu et al, 1999). As HPV may be
persistently present in the skin without evoking any signi®cant
clinical response (Boxman et al, 1997), the stress signal may have
been too weak to evoke a reaction activating this speci®c
pathway.
Second, because NKG2D is also present on most CD8 ab T cells
and gd T cells the presence of MICA molecules may also modulate
antigen-speci®c T cell responses, depending on whether MICA
molecules are induced on the surface of pathogen-infected cells
(Groh et al, 2001). In this way NKG2D could function as a
costimulatory receptor by which the classic immune response may
be modulated.
Third, the strong linkage equilibrium between the MICA gene
and HLA-B could have explained an apparent association between
MICA gene polymorphism and skin cancer, in which the HLA-B
polymorphism could have been the real factor determining the
increased skin cancer risk.
In conclusion, we did not ®nd an association between MICA
gene polymorphism and the occurrence of skin cancer. Apparently,
none of the proposed mechanisms in which the MICA molecule is
involved play an important role in skin carcinogenesis.
We would like to thank all participants of this extensive study, because without their
enthusiastic collaboration the study would not have been possible.
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